MEDP
Medpace Holdings, Inc.558.74
-0.39-0.07%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
15.74BP/E (TTM)
39.07Basic EPS (TTM)
14.30Dividend Yield
0%Recent Filings
8-K
Q3 revenue surges 23.7%
Medpace Holdings reported third-quarter 2025 revenue of $659.9 million, up 23.7% from $533.3 million a year ago, fueled by net new business awards of $789.6 million that lifted the book-to-bill ratio to 1.20x. Backlog grew 2.5% to $3,000.6 million, while GAAP net income hit $111.1 million, or $3.86 per diluted share, with EBITDA rising 24.9% to $148.4 million. The company guides full-year revenue to $2.480-$2.530 billion and net income to $431.0-$439.0 million, yet share repurchases totaling $912.9 million year-to-date trimmed cash to $285.4 million. Strong awards signal pipeline strength.
10-Q
Q2 FY2025 results
Medpace's Q2 revenue climbed 14.2% year-over-year to $603.3 million, fueled by strong gains in metabolic and oncology areas, while operating income rose 20.1% to $126.3 million on tighter cost controls. Gross margins held steady around 70%, but SG&A jumped 12.6% amid higher personnel costs tied to expansion. Diluted EPS edged up to $3.10 from $2.75, aligning with 29.1 million weighted shares despite share repurchases. Operating cash flow for the half-year hit $274.4 million, yielding free cash flow of $258.4 million after $16.0 million in capex (derived), though cash dipped to $46.3 million following $908.4 million in buybacks under a $2.1 billion program. No debt weighs on the balance sheet, with $600 million revolver availability as of quarter-end. Backlog slipped 1.8% to $2.9 billion, signaling steady but tempered demand. Share repurchases accelerated sharply this quarter.
8-K
Medpace Q2 revenue surges 14%
Medpace Holdings boosted Q2 revenue 14.2% to $603.3 million, with net new awards up 12.6% to $620.5 million and a 1.03x book-to-bill ratio, yet backlog dipped 1.8% to $2.87 billion. EBITDA climbed 16.2% to $130.5 million, while the firm repurchased $518.5 million in shares, slashing cash to $46.3 million. It also trimmed its unsecured credit line to $10 million from $600 million on July 17. Strong demand persists.
8-K
Medpace approves extended incentive plan
Medpace Holdings stockholders approved the amended 2016 Incentive Award Plan at the May 16, 2025 annual meeting, extending its expiration to February 6, 2035 without adding shares. This bolsters talent retention amid clinical research demands. Electing August J. Troendle and Dani S. Zander as directors passed handily. Yet, a simple majority voting proposal gained traction.
10-Q
Q1 FY2025 results
Medpace's revenue climbed 9.3% year-over-year to $558.6 million in Q1 FY2025 ended March 31, 2025, fueled by strong gains in metabolic (up 42.8% to $148.0 million) and oncology (up 9.9% to $170.5 million) areas, while operating income rose 9.1% to $113.5 million with margins steady at 20.3%. Diluted EPS grew 14.7% to $3.67 on 31.2 million shares, aligning with net income of $114.6 million after a low 3.0% effective tax rate from share-based compensation benefits. Operating cash flow hit $125.8 million, yielding $115.8 million in free cash flow (derived) after $10.0 million capex, though cash dipped to $441.4 million amid $389.8 million in share repurchases under an expanded $1.1 billion program. No debt weighs on the balance sheet, with $10.0 million revolver availability later boosted to $600.0 million. Backlog slipped 2.1% to $2.8 billion, signaling potential delays in new awards. Yet competition from larger CROs remains a persistent pressure.
IPO
Website
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
CODX
Co-Diagnostics, Inc.
0.25-0.02
ICLR
ICON plc
182.45-1.92
IDXG
Interpace Biosciences, Inc.
1.14-0.02
IQV
IQVIA Holdings, Inc.
221.68-1.95
ISPC
iSpecimen Inc.
0.41-0.01
LH
Labcorp Holdings Inc.
258.11-5.22
MEHCQ
CHROME HLDG CO
3.50+0.00
NOTV
Inotiv, Inc.
0.68-0.02
WAT
Waters Corporation
378.53-6.89